PharmaIN Corporation and Shionogi & Co. have entered into a collaboration agreement with an exclusive two-year option to negotiate a license for the collaboration product.     Shionogi Corp. will make an equity investment of up to $17M in PharmaIN in three transactions.   “We’ve enjoyed working with Shionogi since initial proof of concepts and are excited to expand our collaboration to advance novel, first in class therapy to benefit many millions of patients.  As...